Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for ...

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of ...

Of the 285 heart transplant recipients, 72% were men. After transplantation, women had better outcomes at both 1 year (92.2% ...

Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific ...

Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will present new late-breaking data highlighting the clinical and economic ...

Developed by Ascentage Pharma, olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent Biologics ...

Barresi, who is professor of biological sciences and chair of the Smith College neuroscience program, is creating artworks ...

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing the understanding ...

The 54th International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC 2025), was held from June 15–19, 2025, in Bruges, Belgium. This “Column Watch” installment ...

Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, LA, November 7-10, ...

Summary of the Annual Scientific Meeting (ASM) of the Irish Pain Society (IPS) on October 18, 2025, University of Galway by ...